Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study

Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A... INTRODUCTIONPancreatic ductal adenocarcinoma is a highly lethal disease. It is estimated that in 2017 there will be 53 670 new cases and 43 090 deaths in the United States, which now ranks third among cancer related deaths. At the time of diagnosis, roughly 38% of patients have disease which appears to be localized to the pancreas without obvious metastases. Of those patients deemed operable on clinical grounds, 20‐57% are found to have inoperable disease on exploration depending on the extent and nature of preoperative staging. Most patients present with unsuspected metastatic disease, borderline resectable tumors, or locally advanced, unresectable disease owing to involvement of critical vascular structures: superior mesenteric artery (SMA), celiac trunk, common hepatic artery, or superior mesenteric vein (SMV)/portal vein. Despite recent advances in systemic therapy, even those fortunate few who are able to undergo immediate surgery remain largely incurable, with a 5‐year survival of 25‐30% at best.It is clear from these data that two parallel initiatives are essential if we are to improve patient survival. The first is any strategy that will result in an increase in successful R0 resection of the primary tumor and regional nodes (microscopically margin‐negative resection, in which no gross or microscopic tumor remains http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Surgical Oncology Wiley

Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study

Loading next page...
 
/lp/wiley/primary-systemic-therapy-in-resectable-pancreatic-ductal-oW5BurpcpV
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0022-4790
eISSN
1096-9098
D.O.I.
10.1002/jso.24872
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONPancreatic ductal adenocarcinoma is a highly lethal disease. It is estimated that in 2017 there will be 53 670 new cases and 43 090 deaths in the United States, which now ranks third among cancer related deaths. At the time of diagnosis, roughly 38% of patients have disease which appears to be localized to the pancreas without obvious metastases. Of those patients deemed operable on clinical grounds, 20‐57% are found to have inoperable disease on exploration depending on the extent and nature of preoperative staging. Most patients present with unsuspected metastatic disease, borderline resectable tumors, or locally advanced, unresectable disease owing to involvement of critical vascular structures: superior mesenteric artery (SMA), celiac trunk, common hepatic artery, or superior mesenteric vein (SMV)/portal vein. Despite recent advances in systemic therapy, even those fortunate few who are able to undergo immediate surgery remain largely incurable, with a 5‐year survival of 25‐30% at best.It is clear from these data that two parallel initiatives are essential if we are to improve patient survival. The first is any strategy that will result in an increase in successful R0 resection of the primary tumor and regional nodes (microscopically margin‐negative resection, in which no gross or microscopic tumor remains

Journal

Journal of Surgical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off